Intech Biopharm Corporation (TPEX:6461)

Market Cap	2.73B +8.1%
Revenue (ttm)	117.49M +259.6%
Net Income	-412.53M
EPS	-2.32
Shares Out	178.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	367,955
Open	15.25
Previous Close	15.35
Day's Range	15.25 - 15.55
52-Week Range	14.10 - 26.25
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About Intech Biopharm

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 96
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6461

Financial Performance

In 2025, Intech Biopharm's revenue was 107.53 million, an increase of 170.31% compared to the previous year's 39.78 million. Losses were -389.03 million, 5.66% more than in 2024.